C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research ("SBIR") ...
A study published online Aug. 24 by the journal Pediatrics finds a significant decrease in the use of computed ...
Carilion Clinic, headquartered in Roanoke, Va., consists of seven hospitals and provides health care services for one ...
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
Members of the American Society of Radiologic Technologists can now access the new ASRT Communities, an updated online ...
The American College of Radiology (ACR) recently published a statement on its website confirming that log file ...
![](/sites/default/files/styles/content_feed_medium/public/FCT%20iStream%203qtr%20with%20Tech%20RGB_1.png?itok=M9tQB8sN)
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
RedRick Technologies, a provider of ergonomic radiology furniture, monitor mounting solutions and reading room design ...
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
On April 30, 2015, a major milestone was reached at Ackerman Cancer Center in Jacksonville, Fla., when the first patient ...
Medical equipment manufacturer Quantum Medical Imaging has completed installation of a Quantum Q-Rad-Digital Radiographic System at Colorado Springs Orthopaedic Group in Colorado Springs, Colorado. The sale and installation was facilitated by Medical Imaging Technologies, a certified Quantum/Carestream dealer.
By early childhood, the sight regions of a blind person’s brain respond to sound, especially spoken language, a Johns Hopkins University neuroscientist has found. The results, published this week in The Journal of Neuroscience, suggest that a young, developing brain has a striking capacity for functional adaptation.
Did you know that approximately one-third of all the data in world is created by the healthcare industry and that ...
CompView Medical announced the release of the NuCART, a turn-key, all-in-one mobile boom system with integrated visualization.
August 21, 2015 — Loyola University Medical Center is the first and only hospital in Illinois to offer a new ...
August 21, 2015 — A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish ...
Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...
Non-invasive stereotactic body radiation therapy (SBRT) is effective and well-tolerated by patients with inoperable early-stage or node-negative non-small cell lung cancer (NSCLC) tumors larger than 5 cm, according to a study published in the International Journal of Radiation Oncology Biology Physics.
A national risk model that gauges a woman’s chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than 1 million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher.
![This latest version of Ensight expands the suite of available use cases and provides additional capabilities.](/sites/default/files/styles/content_feed_medium/public/Series%20Impacted%20by%20Endex.png?itok=9v56GnsU)
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
The biggest trends at the recent Association for Medical Imaging Management (AHRA) annual meeting included concerns over ...
ScanMed LLC CEO Randall Jones, Ph.D., MBA, introduced the prostate/pelvic magnetic resonance imaging (MRI) coil dedicated to prostate cancer detection on Omaha's CBS Action News 3 segment "The Morning Blend."
Guided Therapeutics Inc. announced that it has presented the U.S. Food and Drug Administration (FDA) with a plan for advancing the pre-market approval (PMA) application for the LuViva Advanced Cervical Scan. In its “pre-submission” letter, the company also requested a meeting with the agency to finalize the plan.
The ITM Group announced that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next-generation theranostic agent for bone targeted radionuclide therapy and diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone lesions and, when radiolabeled with therapeutic or diagnostic radioisotopes, has shown high potential for positron emission tomography (PET) imaging and endoradiotherapy.
August 20, 2015 — Navidea Biopharmaceuticals announced publication of the results from an investigator-initiated ...
Learn more about myQA, IBA’s unique platform that connects QA applications, people, and know-how through a central ...